Ruxolitinib (S) Size:Solid 2 mg Bay 11-7085 (ECSCs) significantly inhibits

Bay 11-7085 (ECSCs) significantly inhibits the cell proliferation and DNA synthesis of ovarian endometriotic cyst stromal cells and induces apoptosis and the G0/G1 phase cell cycle arrest of these cells

is the potent

under the trade names Kaletra and Aluvia

InChi: InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5

InChiKey: SJDDOCKBXFJEJB-MOKWFATOSA-N

Ruxolitinib (S) Size:Solid 2 mg Bay 11-7085 (ECSCs) significantly inhibitsS Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive